INM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
820.2K
-26.8%
1.1M
-14.1%
1.3M
0
Cost of Revenue
0
-100.0%
636.0K
-11.3%
717.0K
-1.5%
728.1K
0
Gross Profit
0
-100.0%
184.2K
-54.3%
403.2K
-30.1%
576.7K
0
Operating Expenses
2.8M
+22.2%
2.3M
+6.4%
2.2M
-11.5%
2.4M
+18.7%
2.1M
R&D
1.0M
+62.2%
630.6K
+8.4%
581.6K
+416.0%
112.7K
-73.5%
425.4K
SG&A
1.7M
+7.5%
1.6M
+5.8%
1.5M
-32.0%
2.3M
+42.2%
1.6M
Operating Income
-2816353
-32.8%
-2120738
-20.2%
-1763670
+5.7%
-1870606
+9.3%
-2061469
EBITDA
-2765844
-33.8%
-2067537
-20.9%
-1710468
+5.9%
-1817854
+9.5%
-2009164
Net Income
-2966336
-46.3%
-2028223
-17.4%
-1726899
+3.4%
-1788311
+15.7%
-2120930
EPS (Basic)
$-0.73
-43.1%
$-0.51
-15.9%
$-0.44
+63.6%
$-1.21
+37.6%
$-1.94
EPS (Diluted)
$-0.73
-43.1%
$-0.51
-15.9%
$-0.44
+63.6%
$-1.21
+37.6%
$-1.94
Shares (Diluted)
4.0M
+2.4%
4.0M
+0.0%
4.0M
+167.0%
1.5M
+35.2%
1.1M
InMed Pharmaceuticals Inc. Common Shares (INM) โ€” Financials